Impact of methylphenidate on sleep problems in adults with ADHD: a pilot polysomnography study.
ADHD
methylphenidate
polysomnography
sleep disturbances
sleep stage
Journal
Nordic journal of psychiatry
ISSN: 1502-4725
Titre abrégé: Nord J Psychiatry
Pays: England
ID NLM: 100927567
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
27
10
2020
medline:
1
4
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
Attention-deficit hyperactivity disorder (ADHD) is associated with disrupted sleep and circadian rhythm. Medication for ADHD may have side effects aggravating sleep-disturbances, however beneficial effects on ADHD may contribute to improve sleep. This pilot study aims to examine outcomes of first time stimulant treatment on objective and subjective sleep characteristics, and psychiatric symptoms, in adult ADHD patients with pretreatment sleep problems, but without any primary sleep disorder. In total, 9 previously unmedicated adult ADHD subjects who reported pretreatment sleep problems, completed polysomnography (PSG) and questionnaires on subjective sleep disturbances and psychiatric symptoms. Data was collected before and after 6 weeks on first time medication with immediate-release methylphenidate (MPH-IR), mean daily dose 43 mg. Subjects on-medication showed an increased percentage of Stage 2 sleep compared to their non-treated baseline (46.6% versus 55.2%, These findings should be interpreted cautiously given the open-label design and small sample size, and should be examined in larger studies with more rigorous study designs.
Sections du résumé
BACKGROUND
BACKGROUND
Attention-deficit hyperactivity disorder (ADHD) is associated with disrupted sleep and circadian rhythm. Medication for ADHD may have side effects aggravating sleep-disturbances, however beneficial effects on ADHD may contribute to improve sleep.
AIMS
OBJECTIVE
This pilot study aims to examine outcomes of first time stimulant treatment on objective and subjective sleep characteristics, and psychiatric symptoms, in adult ADHD patients with pretreatment sleep problems, but without any primary sleep disorder.
METHODS
METHODS
In total, 9 previously unmedicated adult ADHD subjects who reported pretreatment sleep problems, completed polysomnography (PSG) and questionnaires on subjective sleep disturbances and psychiatric symptoms. Data was collected before and after 6 weeks on first time medication with immediate-release methylphenidate (MPH-IR), mean daily dose 43 mg.
RESULTS
RESULTS
Subjects on-medication showed an increased percentage of Stage 2 sleep compared to their non-treated baseline (46.6% versus 55.2%,
CONCLUSIONS
CONCLUSIONS
These findings should be interpreted cautiously given the open-label design and small sample size, and should be examined in larger studies with more rigorous study designs.
Identifiants
pubmed: 33100096
doi: 10.1080/08039488.2020.1833984
doi:
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM